Science for Life Laboratory, Department of Proteomics, School of Biotechnology, KTH Royal Institute of Technology, Stockholm, Sweden.
Expert Rev Mol Diagn. 2011 Mar;11(2):219-34. doi: 10.1586/erm.10.110.
Current approaches within affinity-based proteomics are driven both by the accessibility and availability of antigens and capture reagents, and by suitable multiplexed technologies onto which these are implemented. By combining planar microarrays and other multiparallel systems with sets of reagents, possibilities to discover new and unpredicted protein-disease associations, either via directed hypothesis-driven or via undirected hypothesis-generating target selection, can be created. In the following stages, the discoveries made during these screening phases have to be verified for potential clinical relevance based on both technical and biological aspects. The use of affinity tools throughout discovery and verification has the potential to streamline the introduction of new markers, as transition into clinically required assay formats appears straightforward. In this article, we summarize some of the current building blocks within array- and affinity-based proteomic profiling with a focus on body fluids, by giving a perspective on how current and upcoming developments in this bioscience could enable a path of pursuit for biomarker discovery.
目前基于亲和力的蛋白质组学方法既受到抗原和捕获试剂的可及性和可用性的驱动,也受到实施这些方法的合适的多重技术的驱动。通过将平面微阵列和其他多平行系统与一组试剂相结合,可以创造出通过有针对性的假设驱动或无针对性的假设生成目标选择来发现新的和未预测的蛋白质-疾病关联的可能性。在接下来的阶段,必须根据技术和生物学方面对这些筛选阶段中发现的内容进行验证,以确定其是否具有潜在的临床相关性。在发现和验证过程中使用亲和工具有可能简化新标记物的引入,因为向临床所需的测定格式的转变似乎很直接。在本文中,我们通过介绍当前在生物科学中的发展如何为生物标志物发现开辟一条探索之路,总结了基于阵列和基于亲和力的蛋白质组学生物标志物分析的一些当前构建模块,重点关注体液。